Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 111.89K shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 54.72K shares, a 69.66% decline from fiscal 2022.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 180.34K shares, a 83.16% decline from fiscal 2021.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 1.07M shares, a 158.25% increase from fiscal 2020.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 414.68K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 111.89K shares derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | 111.89K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 0.00 shares S-1 · filed 2026-05-08 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 0.00 shares derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | 3.63K shares S-1 · filed 2026-05-08 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 3.63K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | 14.68K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 3.63K shares S-1 · filed 2026-05-08 | 32.79K shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | 0.00 shares derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | 38.03K shares S-1 · filed 2026-05-08 |
| 2024-09-30 | 11.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 38.03K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 18.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 26.98K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 8.87K shares 10-Q · filed 2025-05-13 | 63.59K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 54.72K shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 68.06K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 54.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 164.41K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-13 | 149.92K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | 13.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 180.34K shares 10-K · filed 2024-03-14 |
| 2022-09-30 | 96.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 466.57K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | 40.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 569.64K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | 30.42K shares 10-Q · filed 2022-05-09 | 893.61K shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | 299.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 1.07M shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 199.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 880.84K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 364.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 808.22K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | 207.73K shares 10-Q · filed 2022-05-09 | 598.80K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | 109.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 414.68K shares 10-K · filed 2022-02-24 |
| 2020-09-30 | 126.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 305.18K shares derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | 154.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 178.38K shares derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | 23.61K shares 10-Q · filed 2021-05-06 | |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 0.00 shares 10-K · filed 2022-02-24 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 2.01K shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | |
| 2018-03-31 | 2.01K shares 10-Q · filed 2018-05-15 | |
| 2017-12-31 | 2.83K shares 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |